BRIEF published on 06/25/2026 at 18:20, 1 month 13 days ago Pims Technology: Towards Optimizing Cancer Treatments Oncology Personalized Medicine PIMS Technology European Presence Therapeutic Evaluation
BRIEF published on 05/07/2026 at 10:05, 3 months 1 day ago Aton Group is organizing a webinar for shareholders and investors on May 12, 2026 Shareholders Biotechnology Webinar 2025 Results Aton Group
BRIEF published on 04/28/2026 at 18:05, 3 months 10 days ago 2025 Annual Results: Aton Group Strategic Partnerships Biotechnology Business Expansion 2025 Results Aton Group
BRIEF published on 04/23/2026 at 18:05, 3 months 15 days ago B Cell Design innovates in response to the shortage of diagnostic reagents Patented Technology In Vitro Diagnostics Monoclonal Antibodies B Cell Design Aton Group
BRIEF published on 04/01/2026 at 18:05, 4 months 7 days ago Aton Group: Towards a Reduction of Clinical Failures in Pharmaceuticals Clinical Trials Pharmaceutical R&D Aton Group Predictability
BRIEF published on 03/11/2026 at 18:35, 4 months 28 days ago Inoviem Scientific Advances Drug Development with Patient-Centric Approach Personalized Medicine Pharmaceutical Innovation Inoviem Scientific Patient-centric Drug Development Preclinical Programs
PRESS RELEASE published on 03/11/2026 at 18:30, 4 months 28 days ago ATON: UPDATE ON THE ACTIVITIES OF ITS SUBSIDIARY INOVIEM SCIENTIFIC Aton Group's subsidiary, Inoviem Scientific, transforms drug development by prioritizing patient samples & AI technology, accelerating preclinical programs with high-value translational data AI Technology Drug Development Inoviem Scientific Aton Group Patient Sample
BRIEF published on 03/11/2026 at 18:20, 4 months 28 days ago Inoviem Scientific: Advances in Pharmaceutical Development Personalized Medicine Pharmaceutical Development Translational Pharmacology Inoviem Scientific Integrated Platform
BRIEF published on 02/18/2026 at 18:35, 5 months 18 days ago Hadrien Lanvin appointed Deputy Managing Director of the Aton Group Biotechnology Life Sciences Appointment Hadrien Lanvin Aton Group
BRIEF published on 02/18/2026 at 18:35, 5 months 18 days ago Hadrien Lanvin Appointed Deputy CEO of Aton Group Biotechnology Strategic Growth Deputy CEO Hadrien Lanvin Aton Group
Published on 08/07/2026 at 23:15, 23 hours 18 minutes ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 23 hours 33 minutes ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 1 day ago UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 1 day ago Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services
Published on 08/08/2026 at 16:25, 6 hours 8 minutes ago Bybit Sues North Korea and Lazarus Group, Secures Preliminary Injunction Freezing Stolen Assets in Landmark Crypto Asset Recovery Effort
Published on 08/07/2026 at 23:21, 23 hours 12 minutes ago EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 1 day 3 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 19:15, 1 day 3 hours ago ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries
Published on 08/07/2026 at 18:10, 1 day 4 hours ago Stabilus SE: Andreas Jaeger steps down as Chief Financial Officer at his own request
Published on 08/07/2026 at 18:54, 1 day 3 hours ago Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 1 day 3 hours ago Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 17:49, 1 day 4 hours ago Crédit Agricole CIB announced the publication of the Amendment of its 2025 Universal Registration Document
Published on 08/07/2026 at 08:30, 1 day 14 hours ago Disclosure of shares outstanding and voting rights - 07.08.2026
